Forbes: New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients live compared to those on chemotherapy, clinical oncology company Revolution ...

Understanding the Context

CNBC on MSN: Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory ... Reuters on MSN: Revolution Medicines' experimental cancer pill boosts survival in late-stage study Pancreatic cancer is often detected in late stages due to its location in the body. Tumors grow undetected within the gut and is hidden from physical palpi | Immunology ...

Key Insights

Hoodline: Northwestern Cancer Drug Doubles Survival, Gives Chicago A Rare Win On Pancreatic Cancer Northwestern Cancer Drug Doubles Survival, Gives Chicago A Rare Win On Pancreatic Cancer Fierce Biotech: Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial